Retatrutide for muscle growth is a topic generating increasing interest, though the clinical reality differs significantly from many online claims. Retatrutide is an investigational triple incretin receptor agonist developed by Eli Lilly, primarily studied for obesity and type 2 diabetes — not as an anabolic agent. It is not licensed by the MHRA, is unavailable through NHS or regulated private prescribing, and there is no peer-reviewed clinical evidence supporting its use for building skeletal muscle. This article explains how retatrutide works, its current trial status in the UK, safety considerations, and what evidence-based options exist for muscle preservation and body composition.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, developed for obesity and type 2 diabetes — not as an anabolic agent. No clinical evidence supports its use for muscle growth.

Retatrutide is an investigational drug developed by Eli Lilly that belongs to a class of agents known as multi-incretin receptor agonists. Unlike earlier medications in this therapeutic space, retatrutide simultaneously activates three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[1][2] This triple agonist mechanism distinguishes it from dual agonists such as tirzepatide and single agonists such as semaglutide, and is primarily being investigated for the treatment of obesity and type 2 diabetes.^[1][5]

The drug works by mimicking naturally occurring gut hormones that regulate appetite, insulin secretion, and energy expenditure. It has been hypothesised, based on preclinical and early human data, that activation of the glucagon receptor — in addition to GLP-1 and GIP receptors — may promote greater energy expenditure and fat oxidation compared to agents with fewer receptor targets. However, robust human evidence for this mechanism remains limited, and these effects should not be considered established.

In relation to muscle growth, it is important to clarify that retatrutide is not being developed or studied as an anabolic agent. There is no clinical evidence to support its use for building skeletal muscle mass. Some interest has emerged in research circles around whether GLP-1-based therapies might influence body composition — specifically the ratio of fat mass to lean mass during weight loss — but this remains an area of early, exploratory investigation and should not be over-interpreted. Any suggestion that retatrutide directly promotes muscle growth is not supported by peer-reviewed clinical data.

Retatrutide is not licensed for use in the United Kingdom. Further detail on its regulatory status is provided in the final section of this article. Patients should be cautious about claims made outside of regulated medical contexts.

Current Clinical Trial Status in the UK

No large-scale Phase 3 retatrutide trials are known to be actively recruiting in the UK as of July 2025, and the MHRA has not approved it for any indication. Patients can check NIHR Be Part of Research or ClinicalTrials.gov for current study availability.

Retatrutide is currently under clinical investigation, with the most significant data emerging from Phase 2 trials conducted primarily in the United States. In a landmark Phase 2 trial published in The New England Journal of Medicine in 2023, participants receiving the highest dose of retatrutide (12 mg once weekly) achieved an average body weight reduction of approximately 24% over 48 weeks — results that attracted considerable scientific and media attention. However, this trial did not specifically assess muscle mass as a primary or secondary endpoint, and the extent of any changes in lean mass versus fat mass requires further investigation with dedicated body composition measures.

As of the date of writing (July 2025), no large-scale Phase 3 trials for retatrutide are known to be actively recruiting in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has not approved retatrutide for any indication, and it does not feature in current NICE guidance or NHS treatment pathways. Eli Lilly has announced plans to advance retatrutide into Phase 3 development globally, which may in future include UK trial sites, but readers should verify current status directly with authoritative registries, as this position may change.

For those interested in body composition research more broadly, some UK academic institutions are investigating the effects of incretin-based therapies on lean mass preservation during weight loss. These studies are distinct from retatrutide trials and typically involve already-approved agents.

Patients or healthcare professionals seeking information on active UK clinical trials are encouraged to consult NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk), which is the primary UK-facing portal for recruiting studies, and ClinicalTrials.gov, which lists international studies including any with UK sites. The ISRCTN registry (www.isrctn.com) is also a useful resource for UK-registered studies. It is advisable to speak with a GP or specialist before considering participation in any clinical trial.

Potential Risks and Safety Considerations

The most common adverse effects are gastrointestinal, including nausea, vomiting, and diarrhoea, with class-related risks of pancreatitis and gallbladder disease. Loss of lean muscle mass during weight loss is also a recognised concern, particularly in older adults.

As an investigational agent, the full safety profile of retatrutide has not yet been established. Data from Phase 2 trials indicate that the most commonly reported adverse effects are gastrointestinal in nature, consistent with other drugs in the incretin class. These include:

• Nausea (reported in a significant proportion of participants, particularly during dose escalation)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally dose-dependent and tended to diminish over time. However, they led to treatment discontinuation in a subset of trial participants, highlighting that tolerability remains a meaningful clinical consideration. Patients experiencing significant gastrointestinal symptoms should ensure they remain adequately hydrated and seek medical advice if symptoms are severe or persistent.

In common with other agents in the GLP-1 receptor agonist class, there is a potential risk of acute pancreatitis and gallbladder disease (including gallstones and cholecystitis). Although these have not been definitively established as risks specific to retatrutide in early trials, they are recognised class-related concerns. Patients should seek urgent medical attention — by contacting their GP, calling NHS 111, or attending an emergency department — if they experience severe or persistent abdominal pain, particularly if it radiates to the back, or other symptoms that may suggest pancreatitis or gallbladder problems. The MHRA has previously issued drug safety updates on these risks in relation to licensed GLP-1 receptor agonists.^[11]

With respect to muscle mass, a concern shared across the class of GLP-1-based weight loss therapies is the potential for loss of lean muscle tissue alongside fat mass during significant caloric restriction. Preliminary data from retatrutide trials suggest that a proportion of weight lost may include lean mass, though the clinical significance of this in otherwise healthy individuals remains under investigation.^[7] This is particularly relevant for older adults, in whom muscle loss (sarcopenia) carries greater functional consequences.

Other safety signals observed in preclinical and early clinical studies include changes in heart rate and — as with other glucagon receptor agonists — potential effects on hepatic glucose metabolism. Longer-term cardiovascular outcome data are not yet available for retatrutide.

Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) are commonly excluded from trials of GLP-1 receptor agonists as a precautionary measure. This reflects a trial exclusion criterion rather than a blanket contraindication applicable to all licensed GLP-1 receptor agonists in UK clinical practice; prescribers should refer to the relevant Summary of Product Characteristics (SmPC) for licensed agents.

The use of retatrutide — or any investigational weight-loss medicine — is not recommended during pregnancy or breastfeeding. The safety of retatrutide in these situations is unknown, and weight-loss treatment is generally not appropriate during pregnancy.

Anyone experiencing unexplained or concerning symptoms whilst using any investigational or unlicensed medication should seek prompt medical advice from their GP or call NHS 111. Suspected adverse reactions to any medicine can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Availability and Regulatory Position in the UK

Retatrutide is not licensed by the MHRA or EMA and is unavailable through NHS or regulated private prescribing channels. Products sold online as retatrutide may be counterfeit or unsafe; NICE-approved options such as semaglutide and tirzepatide are the appropriate alternatives.

Retatrutide is not currently approved or licensed for use in the United Kingdom. The MHRA has not granted a marketing authorisation for this drug for any indication, including obesity, type 2 diabetes, or muscle growth. Similarly, the European Medicines Agency (EMA) has not issued approval. Retatrutide is therefore not available through standard NHS prescribing channels or licensed private clinics.

Despite this, there is growing concern among healthcare professionals about the availability of unlicensed and unregulated substances — including investigational peptides — through online marketplaces and grey-market suppliers. Some products marketed online as "retatrutide" for purposes such as muscle building or fat loss may be counterfeit, mislabelled, or of unknown purity and concentration. Purchasing or using such products carries significant patient safety risks, including exposure to contaminants, incorrect dosing, and unpredictable pharmacological effects. The MHRA actively monitors and takes enforcement action against the supply of unlicensed medicines in the UK, and provides guidance on the risks of buying medicines online (available at www.^[12]gov.uk/guidance/buying-medicines-online).

For patients seeking evidence-based options for weight management or body composition improvement, NICE-approved pathways remain the appropriate route. NICE has issued technology appraisals supporting the use of semaglutide (Wegovy) and tirzepatide (Mounjaro) within defined clinical criteria for weight management, alongside structured lifestyle interventions.^[13] The availability and commissioning of these treatments within the NHS continues to evolve; patients should check current eligibility criteria with their GP or refer to the NHS website and relevant NICE guidance for the most up-to-date information, as access arrangements may have changed since the date of writing (July 2025).

For muscle preservation and growth, NICE and NHS guidance emphasises resistance exercise training and adequate dietary protein intake as the cornerstones of evidence-based management, particularly in older adults or those undergoing significant weight loss. The NHS provides resources on strength and balance exercises and healthy eating, including protein intake guidance, which are accessible via the NHS website (www.nhs.uk).

Patients are strongly encouraged to discuss any interest in emerging therapies with their GP or a registered specialist, rather than seeking unlicensed products independently. Healthcare professionals can direct patients to reputable sources such as the NHS website (www.nhs.uk), NICE guidelines (www.nice.org.uk), and MHRA drug safety updates (www.gov.uk/drug-safety-updates) for the most current and reliable information. Suspected adverse reactions to any medicine should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions